Charles Schwab Investment Management Inc Cel Sci Corp Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Cel Sci Corp stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 16,481 shares of CVM stock, worth $10,053. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,481

Previous 16,481 -0.0%

Holding current value

$10,053

Previous $19,000 10.53%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $202,088 - $390,861	-78,329 Reduced 82.62%	16,481 $75,000
Q1 2022 May 13, 2022	BUY	$3.93 - $7.7 $1,257 - $2,464	320 Added 0.34%	94,810 $373,000
Q3 2021 Nov 16, 2021	BUY	$7.64 - $12.49 $21,216 - $34,684	2,777 Added 3.03%	94,490 $1.04 Million
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $17,325 - $54,870	1,996 Added 2.22%	91,713 $797,000
Q1 2021 May 17, 2021	BUY	$12.0 - $27.64 $68,640 - $158,100	5,720 Added 6.81%	89,717 $1.37 Million
Q4 2020 Feb 16, 2021	BUY	$11.05 - $16.62 $3,303 - $4,969	299 Added 0.36%	83,997 $980,000
Q3 2020 Nov 13, 2020	SELL	$11.69 - $14.54 $19,721 - $24,528	-1,687 Reduced 1.98%	83,698 $1.07 Million
Q2 2020 Aug 14, 2020	SELL	$9.75 - $17.6 $13,776 - $24,868	-1,413 Reduced 1.63%	85,385 $1.27 Million
Q1 2020 May 15, 2020	BUY	$7.54 - $17.05 $99,249 - $224,429	13,163 Added 17.88%	86,798 $1 Million
Q3 2019 Nov 08, 2019	BUY	$6.0 - $9.6 $18,714 - $29,942	3,119 Added 4.42%	73,635 $659,000
Q2 2019 Aug 09, 2019	BUY	$3.77 - $8.67 $206,833 - $475,662	54,863 Added 350.5%	70,516 $591,000
Q1 2019 May 14, 2019	BUY	$2.58 - $3.54 $40,384 - $55,411	15,653 New	15,653 $56,000

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.5M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Cel Sci Corp Transaction History